In vivo bradykinin B2 receptor activation reduces renal fibrosis.
about
The kallikrein-kinin system in diabetic nephropathyKallikrein-kinin in stem cell therapyDelayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction modelAngiotensin-converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat.Balance between the two kinin receptors in the progression of experimental focal and segmental glomerulosclerosis in miceLabel-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy.Kinin B1 receptor antagonism is equally efficient as angiotensin receptor 1 antagonism in reducing renal fibrosis in experimental obstructive nephropathy, but is not additive.The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease.The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction.Blockade of the kinin B1 receptor ameloriates glomerulonephritisRegulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damage.Obstructive nephropathy: insights from genetically engineered animals.Impact of Mast Cell Chymase on Renal Disease Progression.Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition.The kallikrein-kinin system in health and in diseases of the kidney.Development of a synthetic gene network to modulate gene expression by mechanical forces.Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans.The complement factor 5a receptor 1 has a pathogenic role in chronic inflammation and renal fibrosis in a murine model of chronic pyelonephritisConditional knockout of collecting duct bradykinin B2 receptors exacerbates angiotensin II-induced hypertension during high salt intake.Portal hypertensive response to kinin.Congenital ureteropelvic junction obstruction: human disease and animal models.Renal fibrosis: insight from proteomics in animal models and human disease.New topics in bradykinin research.Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitorsTargeting the 'Janus face' of the B2-bradykinin receptor.Antihypertensive and renoprotective effect of the kinin pathway activated by potassium in a model of salt sensitivity following overload proteinuria.The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis.Cardiac interstitial bradykinin and mast cells modulate pattern of LV remodeling in volume overload in rats.Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.Homocysteine modulates the proteolytic potential of human arterial smooth muscle cells through a reactive oxygen species dependant mechanism.Bradykinin inhibits high glucose- and growth factor-induced collagen synthesis in mesangial cells through the B2-kinin receptor.Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model.Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review).Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors.Serine proteases, inhibitors and receptors in renal fibrosis.Chronic NOS inhibition actuates endothelial-mesenchymal transformation.Unexpected kidney-restricted role for IL-17 receptor signaling in defense against systemic Candida albicans infection.La fibrose tubulo-interstitielle rénaleDelayed Treatment with Plasminogen Activator Inhibitor-1 Decoys Reduces Tubulointerstitial FibrosisIL-17 Receptor Signaling Negatively Regulates the Development of Tubulointerstitial Fibrosis in the Kidney
P2860
Q26827473-5F3EE537-6D9B-4450-811D-27F955309E52Q27010386-2B35E848-580B-45E8-B235-E841C289662EQ28731390-3C26FE3D-88E8-4286-A871-5CC4AC8FB4EFQ30442136-02847A91-8FAA-407C-9901-D51E1C05300DQ33677241-38B48527-4725-4D5E-BF6E-E03018AE0B80Q34634938-35EB0549-2D0B-4A69-8935-5736657E9080Q35037194-DD6DD86A-F1EC-4372-AC7B-81A0926511E5Q35117065-9515E2A6-E63B-4C70-A361-D5123C9D2BB2Q35148421-CBA288D6-FC06-4E06-8878-F2643554ABA1Q35153206-E7E12FD1-EC33-4D96-9EFD-F92807736BFCQ36067015-5871C116-C5AE-4D53-8FDF-09F2CC150B3AQ36232250-DFBFF1EF-1D16-45B4-AFF3-DD378B541DD0Q36682426-4C5FA0D8-EE1C-4637-8CAD-3A5E47DC1838Q36877791-C50A5EA0-6F09-48A4-96AC-8F2A99D7EF28Q37070150-46AAFFE9-3B0C-48B0-A9CF-F35B0F5FDA12Q37084745-89B4F226-2D28-4ED6-9D71-4EAF6B55D39EQ37143371-9905E4E0-3272-40FF-90FA-435CAD2F1725Q37201208-A1BB65B0-ECDB-4280-8FD9-DDAC4E056BA4Q37322338-BD51B206-0E79-41C6-82A0-2980CD209215Q37590180-3DC23356-2D81-45C2-8C6C-078EE13DAD2FQ37777427-97D0E74C-2CA6-4C9E-A41C-929F622A4118Q37828116-4D22E086-CCEA-49AE-A81C-01A482BD6C1DQ37920922-774E7034-9B30-45FB-998F-3DC2FBA24501Q37962590-E73A65B6-BE54-42AB-9584-457DA896B908Q38129928-A0CF123F-7FB8-42C7-B6DD-03E7877F517CQ39172066-4AC1AEAD-F181-413F-82C8-D4EB2E67A8C7Q42104311-2347A8A9-CA45-4A63-8E36-C7A207137018Q42438966-2B608E5B-E1AE-45D1-96AE-E5F8350C00E9Q43262211-CCB7DC37-D600-40BF-A2C3-07CCB6CD46CAQ43269924-A2F75BA8-3114-466E-904C-0A9E4E37C349Q45853275-3AE3BB36-622C-4D14-BABD-487DC2477AF3Q46681465-602564EC-3248-468C-B30D-90D0EDB50603Q47554530-6927A3EC-F5CE-4DFB-80D6-585A139CCF09Q47776900-6612701D-DDA5-4882-A0DA-D1A0B7978F52Q50357092-4BC66BFD-5C75-46B9-A8FF-405CE564BE66Q50715902-0191CD2C-852C-454F-821C-5FDC16C73925Q52714508-66747B76-6745-4C96-8FF3-DBF513622E79Q57718617-BE517362-9BF7-4234-936E-E627A747D18BQ57718662-1ED805B2-A5C9-48E0-9343-9932A557B365Q58567854-41D4E85B-C76E-4A5E-9038-67E55AB7FE99
P2860
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@ast
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@en
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@nl
type
label
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@ast
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@en
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@nl
prefLabel
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@ast
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@en
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@nl
P2093
P2860
P356
P1476
In vivo bradykinin B2 receptor activation reduces renal fibrosis.
@en
P2093
Christiane Pecher
Denis Calise
Jean-Loup Bascands
Jean-Pierre Girolami
Joost P Schanstra
José Miguel Lopez Novoa
Miguel A Arevalo Gomez
Pascale Drogoz
P2860
P304
P356
10.1172/JCI0215493
P407
P577
2002-08-01T00:00:00Z